← Back to Screener
EVOGENE LTD. (EVGN)
Price$0.68
Value ScoreC
Growth ScoreB
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-50.65%
Price vs S&P 500 (4W)-12.94%
VGM Score50.50
Market Capitalization$8.53M
All Metrics
Book Value / Share (Quarterly)$0.13
P/TBV (Annual)2.18x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)30.54%
Cash Flow / Share (Quarterly)$-1.08
Price vs S&P 500 (YTD)-46.84%
Gross Margin (TTM)71.02%
Net Profit Margin (TTM)-392.14%
EPS (TTM)$-1.38
10-Day Avg Trading Volume0.07M
EPS Excl Extra (TTM)$-1.38
Revenue Growth (5Y)-13.11%
EPS (Annual)$-1.08
ROI (Annual)-101.36%
Gross Margin (Annual)-120.56%
Net Profit Margin (5Y Avg)-2057.32%
Cash / Share (Quarterly)$1.25
Revenue Growth QoQ (YoY)708.37%
ROA (Last FY)-42.33%
Revenue Growth TTM (YoY)331.52%
EBITD / Share (TTM)$-1.38
ROE (5Y Avg)-46.94%
Operating Margin (TTM)-457.22%
Cash Flow / Share (Annual)$-1.56
P/B Ratio7.47x
P/B Ratio (Quarterly)8.71x
Net Income / Employee (Annual)$-59,800
EV / Revenue (TTM)2.79x
Net Interest Coverage (TTM)-101.26x
ROA (TTM)-48.03%
EV / EBITDA (TTM)-6.35x
EPS Incl Extra (Annual)$-1.08
Current Ratio (Annual)4.54x
Quick Ratio (Quarterly)2.76x
3-Month Avg Trading Volume0.35M
52-Week Price Return-36.58%
Revenue / Employee (TTM)$41,766,420,000
Tangible BV / Share (Quarterly)$0.13
P/S Ratio (Annual)2.86x
Asset Turnover (Annual)0.06x
52-Week High$2.42
Operating Margin (5Y Avg)-2072.63%
EPS Excl Extra (Annual)$-1.08
CapEx CAGR (5Y)14.69%
Tangible BV CAGR (5Y)-27.61%
26-Week Price Return-34.72%
Quick Ratio (Annual)4.33x
13-Week Price Return-18.09%
Total Debt / Equity (Annual)0.95x
Current Ratio (Quarterly)2.79x
Enterprise Value$2.05M
Revenue / Share Growth (5Y)-20.95%
Asset Turnover (TTM)0.10x
Book Value / Share Growth (5Y)-24.14%
Revenue / Employee (Annual)$21,000
Inventory Turnover (Annual)19.52x
Pretax Margin (Annual)-735.95%
Cash / Share (Annual)$1.49
3-Month Return Std Dev58.64%
Gross Margin (5Y Avg)-168.64%
Net Income / Employee (TTM)$-82,900
ROE (Last FY)-198.12%
Net Interest Coverage (Annual)-3.89x
EPS Basic Excl Extra (Annual)$-1.08
P/FCF (TTM)7.12x
Receivables Turnover (TTM)6.37x
Total Debt / Equity (Quarterly)2.21x
EPS Incl Extra (TTM)$-1.38
Receivables Turnover (Annual)5.33x
ROI (TTM)-56.10%
P/S Ratio (TTM)5.26x
Pretax Margin (5Y Avg)-2054.24%
Revenue / Share (Annual)$0.65
Tangible BV / Share (Annual)$0.33
Price vs S&P 500 (52W)-64.78%
EPS Growth TTM (YoY)37.04%
Year-to-Date Return-35.91%
5-Day Price Return0.71%
EPS Normalized (Annual)$-1.08
ROA (5Y Avg)-36.63%
Net Profit Margin (Annual)-800.77%
Month-to-Date Return-9.62%
Cash Flow / Share (TTM)$-0.46
EBITD / Share (Annual)$-1.64
Operating Margin (Annual)-745.51%
LT Debt / Equity (Annual)0.86x
ROI (5Y Avg)-45.49%
LT Debt / Equity (Quarterly)57.69x
EPS Basic Excl Extra (TTM)$-1.38
P/TBV (Quarterly)8.71x
P/B Ratio (Annual)3.52x
Inventory Turnover (TTM)0.37x
Pretax Margin (TTM)-391.86%
Book Value / Share (Annual)$2.38
Price vs S&P 500 (13W)-27.84%
Beta1.32x
P/FCF (Annual)0.69x
Revenue / Share (TTM)$0.13
ROE (TTM)-38.31%
52-Week Low$0.66
vGradeC
gGradeB
mGradeD
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.60est. -0.28
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.14
4.14
4.14
4.14
Industry Peers — Agricultural Chemicals(9)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
EVGNEVOGENE LTD. | C | B | D | $0.68 |
| NTRNutrien Ltd. Common Shares | B | B | C | $69.57 |
| CFCF Industries Holding, Inc. | B | B | C | $113.30 |
| MOSThe Mosaic Company | B | C | C | $23.33 |
| SMGThe Scotts Miracle-Gro Company | B | D | C | $58.73 |
| UANCVR Partners, LP | B | B | B | $119.99 |
| CBUSCibus, Inc. Class A Common Stock | D | D | D | $1.47 |
| AVDAmerican Vanguard Corporation | B | C | F | $2.60 |
| BIOXBioceres Crop Solutions Corp. Ordinary Shares | B | C | D | $0.48 |
| SNESSenesTech, Inc. Common Stock | B | B | D | $1.69 |
About
Evogene Ltd is a computational biology company that uses its Computational Predictive Biology platform to discover and develop life-science products based on microbes, small molecules, and genetic elements. The company operates across three sectors—agriculture, human health, and industrial applications—through a portfolio of subsidiaries developing agricultural biologicals, seed traits, microbiome therapeutics, and specialty chemicals. Revenue is generated primarily from the agriculture segment.